Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
Related Questions
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?
How are you using CSF cytokine panels in autoimmune encephalitis, if at all?
Would you consider anti-CD20 agents for treatment of multiple sclerosis in patients with history of breast cancer?
If a patient develops itching with their first dose of Tysabri despite pre-treatment, does this indicate that further cycles of Tysabri are contraindicated or do you continue Tysabri at the next cycle?
What is your approach to dosing rituximab in patients with multiple sclerosis?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
How do you treat solitary sclerosis?
What baseline visual testing, if any, do you recommend at diagnosis for patients with multiple sclerosis who deny visual complaints?
